The Critical Path to Therapeutics for the Ataxias (CPTA) Consortium was launched at the end of February 2021.
As a collaborative effort, this semi private partnership unites C-Path, Ataxia Global Initiative, NAF and Ataxia UK as well as partners in the industry and academic research communities including Biohaven Pharmaceuticals, Ionis Pharmaceuticals, Roche Pharmaceuticals, Servier Group, Triplet Therapeutics, uniQure, and Vico Therapeutics and aims at optimizing clinical trials for inherited ataxias.
Click here to find out more.